AbbVie and Xilio Therapeutics announce collaboration and option agreement
by
Contributor since / Followers
Contributor since / Followers
2 months ago
Rasi Bhadramani
- AbbVie (NYSE:ABBV) and Xilio Therapeutics (NASDAQ:XLO) have entered into a collaboration and option-to-license agreement to develop innovative tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, using Xilio’s proprietary technology.
- Shares of Xilio surged 107% in premarket trading.
- As part of the